Epithalon shows clear benefits such as better sleep, less oxidative load, and steadier cycles in small studies
It is described in the research literature as a partial sequence derived from a protein found in human gastric juice
Regulatory Gap : Regulatory bodies (the FDA and European Medicines Agency (EMA)) classify BPC-157 as a research compound, prohibiting its use as an approved therapeutic
First characterised by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s, BPC-157 has since become one of the most widely studied peptides in preclinical research, spanning gastrointestinal biology, musculoskeletal repair, neuroprotection, and cytoprotective signalling
Oral versions of BPC 157 capsules also exist, though research suggests injections may be more effective for localized repair